Trial Profile
First in human PET study of Flutriciclamide (18F-GE180) a novel third generation marker of Human Translocator Protein
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jun 2017
Price :
$35
*
At a glance
- Drugs GEH 120714 (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Diagnostic use; First in man
- 16 Jun 2017 New trial record